Literature DB >> 24423341

Soluble CD163 is associated with CD163 mRNA expression in adipose tissue and with insulin sensitivity in steady-state condition but not in response to calorie restriction.

Jana Kračmerová1, Lenka Rossmeislová, Zuzana Kováčová, Eva Klimčáková, Jan Polák, Michaela Tencerová, Lucia Mališová, Vladimír Štich, Dominique Langin, Michaela Šiklová.   

Abstract

CONTEXT: Soluble CD163 (sCD163) was suggested as a biomarker of insulin sensitivity and CD163 mRNA expression representing macrophage content in adipose tissue (AT).
OBJECTIVE: The aim of this study was to investigate, in cross-sectional and prospective design, the relationship between sCD163 circulating levels and CD163 mRNA expression in adipose tissue and insulin sensitivity assessed by euglycemic-hyperinsulinemic clamp. DESIGN, SETTING, PARTICIPANTS, AND
INTERVENTIONS: Two cohorts of subjects were examined in the study. Cohort 1 included 42 women with a wide range of body mass index (17-48 kg/m(2)); cohort 2 included 27 obese women who followed a dietary intervention consisting of 1 month of a very low-calorie diet and 5 months of a weight-stabilization period. MAIN OUTCOME MEASURES: Serum levels of CD163 and mRNA expression of CD163 and CD68 in sc and visceral (visc) AT were determined, and insulin sensitivity [expressed as glucose disposal rate (GDR)] was measured in cohort 1. In cohort 2, serum levels of CD163, mRNA expressions of CD163, CD68, and CD163-shedding factors [TNF-α-converting enzyme (TACE) and tissue inhibitor of metalloproteinase (TIMP3)] in sc AT were examined and GDR was measured before and during dietary intervention.
RESULTS: In cohort 1, circulating sCD163 correlated with CD163 mRNA levels in both sc and visc AT. sCD163 and CD163 mRNA expression in both fat depots correlated with GDR. In cohort 2, the diet-induced changes of sCD163 levels did not correlate with those of CD163, CD68, TACE, and TIMP3 mRNA levels. Although the pattern of the diet-induced change of sCD163 paralleled that of GDR, there was no correlation between the changes of these two variables.
CONCLUSION: sCD163 correlates with CD163 mRNA expression in sc and visc AT and with whole-body insulin sensitivity in the steady-state condition. These associations are not observed with respect to the diet-induced changes during a weight-reducing hypocaloric diet.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24423341     DOI: 10.1210/jc.2013-3348

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Serum sCD163 as a biomarker of adipose tissue inflammation in obstructive sleep apnoea patients: limits and perspectives.

Authors:  Silke Ryan
Journal:  Eur Respir J       Date:  2017-08-17       Impact factor: 16.671

2.  Serum sCD163 as a biomarker of adipose tissue inflammation in obstructive sleep apnoea patients: limits and perspectives.

Authors:  Denis Monneret; Jean-Philippe Bastard
Journal:  Eur Respir J       Date:  2017-08-17       Impact factor: 16.671

3.  The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.

Authors:  Victoria Cairoli; Elena De Matteo; Paola Casciato; Beatriz Ameigeiras; María Victoria Preciado; Pamela Valva
Journal:  PLoS One       Date:  2022-07-07       Impact factor: 3.752

4.  The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and β-cell Function.

Authors:  Zhila Semnani-Azad; Philip W Connelly; Luke W Johnston; Ravi Retnakaran; Stewart B Harris; Bernard Zinman; Anthony J Hanley
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

5.  Elevated soluble CD163 in gestational diabetes mellitus: secretion from human placenta and adipose tissue.

Authors:  Muhammad Furqan Bari; Martin O Weickert; Kavitha Sivakumar; Sean G James; David R J Snead; Bee Kang Tan; Harpal Singh Randeva; Claire Cecile Bastie; Manu Vatish
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

6.  Macrophage activation marker sCD163 correlates with accelerated lipolysis following LPS exposure: a human-randomised clinical trial.

Authors:  Nikolaj Rittig; Mads Svart; Niels Jessen; Niels Møller; Holger J Møller; Henning Grønbæk
Journal:  Endocr Connect       Date:  2018-01       Impact factor: 3.335

7.  Visceral obesity is associated with increased soluble CD163 concentration in men with type 2 diabetes mellitus.

Authors:  Lars Peter Sørensen; Tina Parkner; Esben Søndergaard; Bo Martin Bibby; Holger Jon Møller; Søren Nielsen
Journal:  Endocr Connect       Date:  2015-03       Impact factor: 3.335

Review 8.  Clinical significance of sCD163 and its possible role in asthma (Review).

Authors:  Yue Zhi; Peng Gao; Xiuqin Xin; Wei Li; Lei Ji; Lin Zhang; Xueyang Zhang; Jie Zhang
Journal:  Mol Med Rep       Date:  2017-03-24       Impact factor: 2.952

9.  Insulin resistance is linked to a specific profile of immune activation in human subjects.

Authors:  Renaud Cezar; Delphine Desigaud; Manuela Pastore; Lucy Kundura; Anne-Marie Dupuy; Chantal Cognot; Thierry Vincent; Christelle Reynes; Robert Sabatier; Elisabeth Maggia; Pierre Corbeau
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

10.  The Association between Monocyte Surface CD163 and Insulin Resistance in Patients with Type 2 Diabetes.

Authors:  Reina Kawarabayashi; Koka Motoyama; Miyuki Nakamura; Yuko Yamazaki; Tomoaki Morioka; Katsuhito Mori; Shinya Fukumoto; Yasuo Imanishi; Atsushi Shioi; Tetsuo Shoji; Masanori Emoto; Masaaki Inaba
Journal:  J Diabetes Res       Date:  2017-12-28       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.